BRPI0913457B8 - Composto e composição farmacêutica - Google Patents
Composto e composição farmacêuticaInfo
- Publication number
- BRPI0913457B8 BRPI0913457B8 BRPI0913457A BRPI0913457A BRPI0913457B8 BR PI0913457 B8 BRPI0913457 B8 BR PI0913457B8 BR PI0913457 A BRPI0913457 A BR PI0913457A BR PI0913457 A BRPI0913457 A BR PI0913457A BR PI0913457 B8 BRPI0913457 B8 BR PI0913457B8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- vmat2
- inhibitor
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
- C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9789608P | 2008-09-18 | 2008-09-18 | |
| US61/097,896 | 2008-09-18 | ||
| PCT/US2009/057480 WO2010044981A2 (en) | 2008-09-18 | 2009-09-18 | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0913457A2 BRPI0913457A2 (pt) | 2020-06-09 |
| BRPI0913457B1 BRPI0913457B1 (pt) | 2021-07-20 |
| BRPI0913457B8 true BRPI0913457B8 (pt) | 2021-08-31 |
Family
ID=42107127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0913457A BRPI0913457B8 (pt) | 2008-09-18 | 2009-09-18 | Composto e composição farmacêutica |
Country Status (20)
| Country | Link |
|---|---|
| US (16) | US8524733B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP3061760B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5616345B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN102186848B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009303758B8 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0913457B8 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2972242A1 (cg-RX-API-DMAC7.html) |
| CY (1) | CY1120060T1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK2326643T3 (cg-RX-API-DMAC7.html) |
| ES (4) | ES2425623T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20180239T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE038158T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3061760T (cg-RX-API-DMAC7.html) |
| NO (1) | NO3061760T3 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ591615A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3061760T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3061760T (cg-RX-API-DMAC7.html) |
| SI (1) | SI3061760T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT201800067T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010044981A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO3061760T3 (cg-RX-API-DMAC7.html) * | 2008-09-18 | 2018-04-07 | ||
| PT2499139E (pt) * | 2009-11-10 | 2014-02-10 | Pfizer | Inibidores de n1-pirazolospirocetona acetil-coa carboxilase |
| CA2801061A1 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| PL3222266T3 (pl) | 2010-08-27 | 2018-10-31 | Sienna Biopharmaceuticals, Inc. | Kompozycje i sposoby do termomodulacji celowanej |
| US9572880B2 (en) | 2010-08-27 | 2017-02-21 | Sienna Biopharmaceuticals, Inc. | Ultrasound delivery of nanoparticles |
| WO2012081031A1 (en) * | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| NZ705372A (en) * | 2012-09-18 | 2018-07-27 | Auspex Pharmaceuticals Inc | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| KR20200106984A (ko) | 2012-10-11 | 2020-09-15 | 나노콤포식스, 인크. | 은 나노플레이트 조성물 및 방법 |
| HK1219095A1 (zh) * | 2013-01-31 | 2017-03-24 | Auspex Pharmaceuticals, Inc. | Vmat2的benzoquinolone抑制剂 |
| WO2015048370A1 (en) * | 2013-09-27 | 2015-04-02 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| EP3071565A4 (en) * | 2013-11-22 | 2017-08-02 | Auspex Pharmaceuticals, Inc. | Methods of treating abnormal muscular activity |
| WO2015077521A1 (en) * | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2930744A1 (en) | 2013-12-03 | 2015-06-11 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| EP3099299A4 (en) | 2014-01-27 | 2017-10-04 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| RU2021128797A (ru) * | 2014-02-07 | 2021-11-26 | Ньюрокрайн Байосайенсиз, Инк. | Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение |
| KR20160117596A (ko) * | 2014-02-07 | 2016-10-10 | 오스펙스 파마슈티칼스, 인코포레이티드 | 신규 제약 제제 |
| JP6635945B2 (ja) | 2014-05-06 | 2020-01-29 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 多動性運動障害を処置するためのｖｍａｔ２インヒビター |
| MA41557A (fr) * | 2015-02-18 | 2017-12-26 | Auspex Pharmaceuticals Inc | Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2 |
| CN114796209A (zh) | 2015-03-06 | 2022-07-29 | 奥斯拜客斯制药有限公司 | 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物 |
| WO2016154017A1 (en) * | 2015-03-20 | 2016-09-29 | Sienna Biopharmaceuticals, Inc. | Enhanced efficacy and targeted topical delivery of drugs to skin with nanoparticles |
| JP7109360B2 (ja) | 2015-10-30 | 2022-07-29 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | バルベナジン塩およびその多形体 |
| CA3009169A1 (en) | 2015-12-23 | 2017-06-29 | Neurocrine Biosciences, Inc. | Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
| US10479787B2 (en) | 2016-04-22 | 2019-11-19 | Lupin Limited | Process for preparation of tetrabenazine and deutetrabenazine |
| WO2017221169A1 (en) | 2016-06-24 | 2017-12-28 | Lupin Limited | Premixes of deutetrabenazine |
| CN107936008B (zh) * | 2016-10-13 | 2022-06-14 | 泰州华元医药科技有限公司 | 氘代化合物及其医药用途 |
| JP2020500875A (ja) | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| US10703750B2 (en) | 2017-01-10 | 2020-07-07 | Sandoz Ag | Crystalline valbenazine free base |
| EA201991782A1 (ru) | 2017-01-27 | 2021-09-23 | Нейрокрин Байосайенсиз, Инк. | Способы введения некоторых vmat2-ингибиторов |
| CA3054238A1 (en) | 2017-02-27 | 2018-08-30 | Sandoz Ag | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| JP7608050B2 (ja) * | 2017-03-15 | 2025-01-06 | オースペックス ファーマシューティカルズ インコーポレイテッド | デューテトラベナジンの類似体、その調製及び使用 |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| CN111372567B (zh) | 2017-09-21 | 2024-03-15 | 纽罗克里生物科学有限公司 | 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒 |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| WO2019074492A1 (en) | 2017-10-10 | 2019-04-18 | Obrien Christopher F | METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS |
| US10786495B2 (en) * | 2017-10-10 | 2020-09-29 | The Regents Of The University Of California | Vesicular monoamine transporter 2 inhibitors for treating stuttering |
| WO2019130252A2 (en) * | 2017-12-29 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing deutetrabenazine |
| CN111655243A (zh) | 2018-01-29 | 2020-09-11 | 乔纳森·萨克纳-伯恩斯坦 | 在人类神经系统疾病中调节多巴胺的方法 |
| WO2019150387A1 (en) * | 2018-02-01 | 2019-08-08 | Alaparthi Lakshmi Prasad | A novel process for preparation of deutetrabenazine |
| WO2019166962A1 (en) | 2018-03-01 | 2019-09-06 | Mylan Laboratories Ltd | Deutetrabenazine polymorphs and methods for their preparation |
| US12144899B2 (en) * | 2018-04-25 | 2024-11-19 | Shinkei Therapeutics, Inc. | Tetrabenazine transdermal delivery device |
| US10632107B2 (en) | 2018-05-14 | 2020-04-28 | Apotex Inc. | Crystalline forms of benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| MX2020013004A (es) | 2018-06-14 | 2021-02-17 | Neurocrine Biosciences Inc | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
| CN108794337A (zh) * | 2018-07-10 | 2018-11-13 | 上海华堇生物技术有限责任公司 | 一种3,4-二羟基-β-硝基苯乙烯的新制备方法 |
| IL320987A (en) | 2018-08-15 | 2025-07-01 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| MA53904A (fr) | 2018-10-18 | 2021-08-25 | Oncopeptides Ab | Composés contenant du deutérium |
| KR20210114946A (ko) * | 2018-12-13 | 2021-09-24 | 오스펙스 파마슈티칼스, 인코포레이티드 | 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진 |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| PE20230852A1 (es) | 2020-06-10 | 2023-05-29 | Auspex Pharmaceuticals Inc | Formas farmaceuticas osmoticas que comprenden deutetrabenazina y metodos de uso de las mismas |
| KR20230067636A (ko) | 2020-09-17 | 2023-05-16 | 오스펙스 파마슈티칼스, 인코포레이티드 | 듀테트라베나진을 포함하는 다중미립자 제형 |
| WO2022081532A1 (en) | 2020-10-12 | 2022-04-21 | Auspex Pharmaceuticals, Inc. | Gastro retentive dosage forms comprising deutetrabenazine |
| AU2022241988A1 (en) | 2021-03-22 | 2023-10-12 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors and methods of use |
| MX2023014827A (es) | 2021-06-30 | 2024-01-15 | Neurocrine Biosciences Inc | Valbenazina para usarse en el tratamiento complementario de la esquizofrenia. |
| JP2024535862A (ja) | 2021-09-17 | 2024-10-02 | オースペックス ファーマシューティカルズ インコーポレイテッド | デューテトラベナジンを含む多粒子剤形 |
| WO2023133201A1 (en) | 2022-01-05 | 2023-07-13 | K36 Therapeutics, Inc. | Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions |
| IL315181A (en) | 2022-03-07 | 2024-10-01 | Neurocrine Biosciences Inc | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
| IL317235A (en) | 2022-06-08 | 2025-01-01 | Auspex Pharmaceuticals Inc | Osmotic dosage forms comprising ditetrabenzene and methods of using the same |
| WO2025038959A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| TW202521119A (zh) | 2023-08-17 | 2025-06-01 | 美商紐羅克里生物科學有限公司 | 用於投與特定vmat2抑制劑之方法 |
| WO2025096823A1 (en) | 2023-11-01 | 2025-05-08 | Neurocrine Biosciences, Inc. | Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine |
| WO2025259267A1 (en) | 2024-06-11 | 2025-12-18 | Vector Vitale Ip Llc | Pharmaceutical compositions for modulating inflammation and oxidative stress comprising chemically enriched elements |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2830993A (en) | 1958-04-15 | Quinolizine derivatives | ||
| US3045021A (en) * | 1959-09-24 | 1962-07-17 | Hoffmann La Roche | Preparation of substituted 2-oxobenzoquinolizines |
| AT238201B (de) * | 1961-03-28 | 1965-01-25 | Mta | Verfahren zur Herstellung von Chinolizinderivaten |
| US4316897A (en) * | 1980-09-10 | 1982-02-23 | Hoffmann-La Roche Inc. | Method of lowering serum prolactin |
| AU707748B2 (en) * | 1994-03-25 | 1999-07-22 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| EP1104760B1 (en) * | 1999-12-03 | 2003-03-12 | Pfizer Products Inc. | Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents |
| EP1134290A3 (en) * | 2000-03-14 | 2004-01-02 | Pfizer Products Inc. | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| CA2546395A1 (en) * | 2003-11-21 | 2005-06-09 | Memory Pharmaceutical Corporation | Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| AU2006206458B2 (en) | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US20080033011A1 (en) * | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| WO2007130365A2 (en) | 2006-05-02 | 2007-11-15 | The Trustees Of The University Of Pennsylvania | Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents |
| PT2081929E (pt) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados |
| EP2078026B1 (en) | 2006-11-21 | 2012-01-04 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses |
| US20100204258A1 (en) * | 2007-03-12 | 2010-08-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for modulating insulin secretion and glucose metabolism |
| US8008500B2 (en) * | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
| WO2009003226A1 (en) | 2007-06-29 | 2009-01-08 | Clarencew Pty Ltd | Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration |
| WO2009124357A1 (en) | 2008-04-10 | 2009-10-15 | Malvin Leonard Eutick | Fast dissolving oral formulations for critical drugs |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| NO3061760T3 (cg-RX-API-DMAC7.html) | 2008-09-18 | 2018-04-07 | ||
| US20100113496A1 (en) * | 2008-09-25 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of vmat2 |
| JP2013501810A (ja) | 2009-08-12 | 2013-01-17 | ヴァリーント インターナショナル（バルバドス）エスアールエル | 医薬組成物 |
| AU2011218805A1 (en) | 2010-02-24 | 2012-08-30 | Auspex Pharmaceuticals, Inc. | Trimethoxyphenyl inhibitors of tyrosine kinase |
| CA2801061A1 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
-
2009
- 2009-09-18 NO NO15185548A patent/NO3061760T3/no unknown
- 2009-09-18 US US12/562,621 patent/US8524733B2/en active Active
- 2009-09-18 ES ES09820972T patent/ES2425623T3/es active Active
- 2009-09-18 NZ NZ591615A patent/NZ591615A/en unknown
- 2009-09-18 PT PT151855483T patent/PT3061760T/pt unknown
- 2009-09-18 CN CN200980141378.0A patent/CN102186848B/zh active Active
- 2009-09-18 WO PCT/US2009/057480 patent/WO2010044981A2/en not_active Ceased
- 2009-09-18 DK DK09820972.9T patent/DK2326643T3/da active
- 2009-09-18 EP EP15185548.3A patent/EP3061760B1/en active Active
- 2009-09-18 CA CA2972242A patent/CA2972242A1/en not_active Abandoned
- 2009-09-18 ES ES15185548.3T patent/ES2652289T3/es active Active
- 2009-09-18 SM SM20180067T patent/SMT201800067T1/it unknown
- 2009-09-18 ES ES13160950.5T patent/ES2563820T3/es active Active
- 2009-09-18 SI SI200931797T patent/SI3061760T1/en unknown
- 2009-09-18 JP JP2011527995A patent/JP5616345B2/ja active Active
- 2009-09-18 LT LTEP15185548.3T patent/LT3061760T/lt unknown
- 2009-09-18 PL PL15185548T patent/PL3061760T3/pl unknown
- 2009-09-18 BR BRPI0913457A patent/BRPI0913457B8/pt active IP Right Grant
- 2009-09-18 DK DK15185548.3T patent/DK3061760T3/en active
- 2009-09-18 CA CA2736409A patent/CA2736409C/en active Active
- 2009-09-18 EP EP13160950.5A patent/EP2610254B1/en not_active Not-in-force
- 2009-09-18 CN CN201410524867.7A patent/CN104311552A/zh active Pending
- 2009-09-18 AU AU2009303758A patent/AU2009303758B8/en active Active
- 2009-09-18 ES ES17199778T patent/ES2896678T3/es active Active
- 2009-09-18 HU HUE15185548A patent/HUE038158T2/hu unknown
- 2009-09-18 EP EP17199778.6A patent/EP3345905B1/en active Active
- 2009-09-18 EP EP09820972.9A patent/EP2326643B1/en active Active
-
2013
- 2013-07-03 US US13/934,960 patent/US20130296360A1/en not_active Abandoned
-
2014
- 2014-03-25 US US14/224,883 patent/US20140206712A1/en not_active Abandoned
- 2014-03-25 US US14/225,010 patent/US20140206713A1/en not_active Abandoned
- 2014-08-08 US US14/454,911 patent/US20140350044A1/en not_active Abandoned
- 2014-09-11 JP JP2014185634A patent/JP5970037B2/ja active Active
- 2014-10-15 US US14/515,047 patent/US20150080427A1/en not_active Abandoned
-
2015
- 2015-07-23 US US14/807,364 patent/US20150328207A1/en not_active Abandoned
-
2016
- 2016-02-11 US US15/041,571 patent/US20160158220A1/en not_active Abandoned
- 2016-04-08 US US15/094,517 patent/US20160220558A1/en not_active Abandoned
- 2016-07-08 JP JP2016136178A patent/JP6138322B2/ja active Active
- 2016-09-01 US US15/254,912 patent/US20160367548A1/en not_active Abandoned
- 2016-09-06 US US15/257,372 patent/US20160375005A1/en not_active Abandoned
-
2017
- 2017-02-28 US US15/445,402 patent/US20170166562A1/en not_active Abandoned
-
2018
- 2018-02-07 HR HRP20180239TT patent/HRP20180239T1/hr unknown
- 2018-02-07 CY CY20181100152T patent/CY1120060T1/el unknown
- 2018-12-05 US US16/210,077 patent/US20190375746A1/en not_active Abandoned
-
2020
- 2020-03-17 US US16/821,067 patent/US20200347048A1/en not_active Abandoned
-
2021
- 2021-11-05 US US17/519,922 patent/US20220267317A1/en not_active Abandoned
-
2025
- 2025-03-17 US US19/081,808 patent/US20250326747A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0913457B8 (pt) | Composto e composição farmacêutica | |
| CY1113011T1 (el) | Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην | |
| BRPI0819328A8 (pt) | Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos | |
| BRPI0715579A2 (pt) | "composto, composição farmacêutica e uso de um composto" | |
| EP4345100A3 (en) | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 | |
| CR11861A (es) | Compuestos organicos | |
| CY1115919T1 (el) | Ενωσεις ενεργοποιησης τελομερασης και μεθοδοι χρησης αυτων | |
| SV2008003088A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen | |
| EA200800321A1 (ru) | Ингибиторы гистондеацетилазы | |
| MX2010002904A (es) | N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv). | |
| DK2049513T3 (da) | Piperidinylsubstituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1 | |
| CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
| BRPI1015043A2 (pt) | derivados de diazahomoadamantano e métodos de uso dos mesmos | |
| CY1116048T1 (el) | Μια κρυσταλλικη μορφη τιγεκυκλινης και διαδικασιες για την παρασκευη της | |
| BRPI0507903A (pt) | derivados de quinazolina e composição farmacêutica compreendendo os mesmos | |
| DOP2010000329A (es) | Inhibidores de la renina | |
| ATE440833T1 (de) | Antithrombotische diamide | |
| CY1115623T1 (el) | Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ | |
| NO20085317L (no) | Imidazoazepinonforbindelser | |
| UA86119C2 (ru) | Амидные пролекарства гемцитабина, их композиции и применение | |
| EA200701810A1 (ru) | Производное изоксазолина и новый способ его получения | |
| CY1113279T1 (el) | Φαρμακευτικη συνθεση 271 | |
| ECSP066751A (es) | Piperidinilcarbonil-pirrolidinas y su uso como agonistas de melanocortina | |
| UY32247A (es) | Nuevos compuestos de aminociclohexilo, composiciones farmacéuticas de los mismos y aplicaciones | |
| NO20074528L (no) | Substituerte pyrroler, sammensetninger, fremgangsmate for fremstilling og anvendelse av samme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/07/2021, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2637 DE 20/07/2021 QUANTO AO PRAZO DE VALIDADE DE 20 (VINTE) ANOS CONTADOS DE 18/09/2009. |